Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Odalasvir and AL-335 in Healthy Japanese Subjects
NCT02821858Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of odalasvir and adafosbuvir in hepatitis C (HCV) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Concentration of Odalasvir, Time to Reach Maximum Observed Concentration of Odalasvir and 8 more. Started Jun 2016; status: completed.
02
Drugs
odalasviradafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02821858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821858.